AP2015008741A0 - Benzimidazolone derivatives as bromodomain inhibitors - Google Patents

Benzimidazolone derivatives as bromodomain inhibitors

Info

Publication number
AP2015008741A0
AP2015008741A0 AP2015008741A AP2015008741A AP2015008741A0 AP 2015008741 A0 AP2015008741 A0 AP 2015008741A0 AP 2015008741 A AP2015008741 A AP 2015008741A AP 2015008741 A AP2015008741 A AP 2015008741A AP 2015008741 A0 AP2015008741 A0 AP 2015008741A0
Authority
AP
ARIPO
Prior art keywords
bromodomain inhibitors
benzimidazolone derivatives
benzimidazolone
derivatives
bromodomain
Prior art date
Application number
AP2015008741A
Other languages
English (en)
Inventor
Jeff Zablocki
Hai Yang
David Sperandio
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AP2015008741A0 publication Critical patent/AP2015008741A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AP2015008741A 2013-03-28 2014-03-27 Benzimidazolone derivatives as bromodomain inhibitors AP2015008741A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361805995P 2013-03-28 2013-03-28
US201361860230P 2013-07-30 2013-07-30
PCT/US2014/032031 WO2014160873A1 (en) 2013-03-28 2014-03-27 Benzimidazolone derivatives as bromodomain inhibitors

Publications (1)

Publication Number Publication Date
AP2015008741A0 true AP2015008741A0 (en) 2015-09-30

Family

ID=50897885

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008741A AP2015008741A0 (en) 2013-03-28 2014-03-27 Benzimidazolone derivatives as bromodomain inhibitors

Country Status (35)

Country Link
US (2) US20160031868A1 (ru)
EP (1) EP2978759B1 (ru)
JP (1) JP6339175B2 (ru)
KR (1) KR101847698B1 (ru)
CN (1) CN105102453B (ru)
AP (1) AP2015008741A0 (ru)
AU (1) AU2014241152B2 (ru)
BR (1) BR112015024078A2 (ru)
CA (1) CA2907502C (ru)
CL (1) CL2015002871A1 (ru)
CR (1) CR20150515A (ru)
CY (1) CY1119165T1 (ru)
DK (1) DK2978759T3 (ru)
EA (1) EA029497B1 (ru)
ES (1) ES2626397T3 (ru)
HK (1) HK1220692A1 (ru)
HR (1) HRP20170750T1 (ru)
HU (1) HUE034772T2 (ru)
IL (1) IL241186A0 (ru)
LT (1) LT2978759T (ru)
MD (1) MD4531C1 (ru)
MX (1) MX2015013798A (ru)
MY (1) MY176634A (ru)
NZ (1) NZ711586A (ru)
PE (1) PE20151982A1 (ru)
PH (1) PH12015502246A1 (ru)
PL (1) PL2978759T3 (ru)
PT (1) PT2978759T (ru)
RS (1) RS56050B1 (ru)
SG (1) SG11201507926RA (ru)
SI (1) SI2978759T1 (ru)
TW (1) TWI530499B (ru)
UY (1) UY35516A (ru)
WO (1) WO2014160873A1 (ru)
ZA (1) ZA201506356B (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2118074T1 (sl) 2007-02-01 2014-05-30 Resverlogix Corp. Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni
CN105859639A (zh) 2009-03-18 2016-08-17 雷斯韦洛吉克斯公司 新的抗炎剂
CN103945848B (zh) 2011-11-01 2016-09-07 雷斯韦洛吉克斯公司 被取代的喹唑啉酮的口服即释制剂
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
CA2895905A1 (en) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
KR102355670B1 (ko) 2013-03-15 2022-02-08 인사이트 홀딩스 코포레이션 Bet 단백질 저해제로서의 삼환식 복소환
SG10201710705UA (en) * 2013-06-21 2018-02-27 Zenith Epigenetics Ltd Novel bicyclic bromodomain inhibitors
US9662311B2 (en) * 2013-06-21 2017-05-30 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
CA2917319A1 (en) 2013-07-08 2015-01-15 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
EP3027604B1 (en) 2013-07-31 2019-02-20 Zenith Epigenetics Ltd. Novel quinazolinones as bromodomain inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
UA119870C2 (uk) 2014-04-23 2019-08-27 Інсайт Корпорейшн 1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET
ES2855225T3 (es) 2014-09-15 2021-09-23 Incyte Corp Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
JP6930913B2 (ja) 2014-10-14 2021-09-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California 炎症を阻害するためのcdk9及びbrd4阻害剤の使用法
CA2966298A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
CA2966449A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
EP3233846A4 (en) 2014-12-17 2018-07-18 Zenith Epigenetics Ltd. Inhibitors of bromodomains
JO3789B1 (ar) 2015-03-13 2021-01-31 Resverlogix Corp التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
GB201504689D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
AR106520A1 (es) 2015-10-29 2018-01-24 Incyte Corp Forma sólida amorfa de un inhibidor de proteína bet
US11225481B2 (en) 2015-12-29 2022-01-18 Centre National De La Recherche Scientifique Xanthine derivative inhibitors of BET proteins
DK3472157T3 (da) 2016-06-20 2023-05-01 Incyte Corp Krystallinske faste former af en bet-inhibitor
US20180179191A1 (en) * 2016-11-22 2018-06-28 Gilead Sciences, Inc. Synthesis of a compound that modulates the activity of bromodomain-containing proteins
EP3707139B1 (en) 2017-11-06 2022-02-16 Centre National de la Recherche Scientifique Xanthine derivatives and uses thereof as inhibitors of bromodomains of bet proteins
CN111712496B (zh) * 2017-12-20 2023-05-02 贝达药业股份有限公司 作为溴结构域蛋白质抑制剂的化合物和组合物
CN113365699B (zh) * 2019-02-02 2024-06-14 石药集团中奇制药技术(石家庄)有限公司 靶向泛素化降解brd4蛋白化合物及其制备方法和应用
CN109912584B (zh) * 2019-03-22 2021-08-13 中国药科大学 一种具有抗肿瘤活性的brd4蛋白抑制剂及其制备方法和应用
CN114502534A (zh) 2019-09-30 2022-05-13 协和麒麟株式会社 Bet降解剂
WO2021237111A1 (en) * 2020-05-21 2021-11-25 Stemsynergy Therapeutics, Inc. Notch inhibitors and uses thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN117821344B (zh) * 2024-03-06 2024-07-26 江苏古道农业科技有限公司 一种草甘膦降解菌及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
JP2010535773A (ja) 2007-08-10 2010-11-25 グラクソスミスクライン エルエルシー ウイルス感染を治療するための窒素含有二環式化学物質
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP3009427B1 (en) 2011-03-03 2019-12-18 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
GB201114103D0 (en) * 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
SG10201710705UA (en) * 2013-06-21 2018-02-27 Zenith Epigenetics Ltd Novel bicyclic bromodomain inhibitors

Also Published As

Publication number Publication date
LT2978759T (lt) 2017-05-25
PT2978759T (pt) 2017-05-31
SI2978759T1 (sl) 2017-05-31
ZA201506356B (en) 2017-08-30
MD20150104A2 (ru) 2016-02-29
KR101847698B1 (ko) 2018-04-10
TWI530499B (zh) 2016-04-21
AU2014241152A1 (en) 2015-09-17
CL2015002871A1 (es) 2016-05-13
HK1220692A1 (zh) 2017-05-12
CY1119165T1 (el) 2018-02-14
RS56050B1 (sr) 2017-09-29
CN105102453B (zh) 2018-04-06
HUE034772T2 (en) 2018-02-28
AU2014241152B2 (en) 2016-11-03
US9255089B2 (en) 2016-02-09
PH12015502246A1 (en) 2016-02-01
EP2978759B1 (en) 2017-03-15
MD4531B1 (ru) 2017-11-30
JP2016515584A (ja) 2016-05-30
DK2978759T3 (da) 2017-06-19
CA2907502C (en) 2018-02-27
US20160031868A1 (en) 2016-02-04
JP6339175B2 (ja) 2018-06-06
PL2978759T3 (pl) 2017-08-31
MY176634A (en) 2020-08-19
MX2015013798A (es) 2016-02-16
EA201591455A1 (ru) 2016-01-29
SG11201507926RA (en) 2015-10-29
PE20151982A1 (es) 2016-01-28
CA2907502A1 (en) 2014-10-02
NZ711586A (en) 2016-09-30
EP2978759A1 (en) 2016-02-03
TW201504233A (zh) 2015-02-01
BR112015024078A2 (pt) 2017-07-18
ES2626397T3 (es) 2017-07-24
CR20150515A (es) 2015-12-01
CN105102453A (zh) 2015-11-25
EA029497B1 (ru) 2018-04-30
KR20150135476A (ko) 2015-12-02
WO2014160873A1 (en) 2014-10-02
UY35516A (es) 2014-09-30
US20140296246A1 (en) 2014-10-02
HRP20170750T1 (hr) 2017-07-28
IL241186A0 (en) 2015-11-30
MD4531C1 (ru) 2018-06-30

Similar Documents

Publication Publication Date Title
HK1220692A1 (zh) 作為布羅莫結構域抑制劑的苯並咪唑酮衍生物
HK1222646A1 (zh) 作為溴結構域抑制劑的苯並咪唑衍生物
IL256946B (en) Bromodomain inhibitors
HK1224297A1 (zh) 布羅莫結構域抑制劑
IL241123A0 (en) Dihydro-pyrrolopyridinones as inhibitors of bromo sites
HK1223090A1 (zh) -氮雜吲哚衍生物